177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

PurposeThere is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled...

Full description

Bibliographic Details
Main Authors: Ting Bu, Lulu Zhang, Fei Yu, Xiaochen Yao, Wenyu Wu, Pengjun Zhang, Liang Shi, Shiming Zang, Qingle Meng, Yudan Ni, Guoqiang Shao, Xuefeng Qiu, Shuyue Ai, Ruipeng Jia, Hongqian Guo, Feng Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
177Lu
prostate cancer
metastatic castration-resistant prostate cancer (mCRPC)
prostate-specific membrane antigen (PSMA)
radioligand therapy (RLT)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.835956/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.835956/full

Similar Items